Searching the Staphylococcal Toxic Shock Syndrome Toxin -1 in Septic Children with negative Cultures: A Comparative

Samileh Noorbakhsh1, Ali Asghar Rabiei2, Ali Akbar Rahbarimanesh3

  • 1Department of Pediatric Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.

Insights

Staphylococcal Toxic Shock Syndrome Toxin-1 (TSST-1) may play a role in pediatric sepsis, even with negative blood cultures. Early anti-staphylococcal treatment is crucial for toxic children presenting with sepsis symptoms.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Immunology

Background:

  • Bacterial sepsis is a significant concern in pediatric populations.
  • Staphylococcus aureus produces exotoxins like TSST-1, a superantigen (SAg), implicated in T cell activation and inflammation.
  • SAgs are increasingly recognized for their role in pediatric sepsis and septic shock pathogenesis.

Purpose of the Study:

  • To compare the prevalence of staphylococcal TSST-1 (SAgs) in children with sepsis symptoms and negative blood cultures against a control group.
  • To investigate the association between TSST-1 and sepsis/septic shock in pediatric patients.

Main Methods:

  • A cross-sectional study conducted over two years in Tehran, Iran.
  • Involved 44 children with sepsis symptoms and 45 controls.
  • TSST-1 (SAgs) detection using polymerase chain reaction (PCR) in blood samples; data analyzed with SPSS-16.

Main Results:

  • TSST-1 was detected in 14% of sepsis cases with negative blood cultures for S. aureus.
  • This prevalence was significantly higher compared to the control group (2%, P=0.05).
  • Other bacteria were identified in 5 cases with negative TSST-1.

Conclusions:

  • TSST-1 (SAgs) likely contributes to the progression of sepsis and septic shock in children, particularly when blood cultures are negative for S. aureus.
  • Prompt anti-staphylococcal treatment is recommended for toxic pediatric patients with sepsis symptoms, irrespective of blood culture results.
  • Targeting SAgs with suppressants may offer therapeutic benefits against downstream inflammatory events.
Abstract